Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024

BUY
$2.12 - $4.18 $24,312 - $47,936
11,468 Added 106.68%
22,218 $89,000
Q3 2023

Nov 09, 2023

BUY
$2.66 - $10.04 $17,343 - $65,460
6,520 Added 154.14%
10,750 $28,000
Q2 2023

Aug 11, 2023

SELL
$7.28 - $11.82 $19,080 - $30,980
-2,621 Reduced 38.26%
4,230 $39,000
Q1 2023

May 12, 2023

BUY
$5.21 - $14.05 $11,498 - $31,008
2,207 Added 47.52%
6,851 $60,000
Q4 2022

Feb 08, 2023

BUY
$4.69 - $8.36 $21,780 - $38,823
4,644 New
4,644 $23,000
Q2 2022

Aug 10, 2022

SELL
$5.04 - $14.05 $10,286 - $28,676
-2,041 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$8.75 - $14.51 $13,361 - $22,156
-1,527 Reduced 42.8%
2,041 $24,000
Q4 2021

Feb 14, 2022

BUY
$8.98 - $20.09 $32,040 - $71,681
3,568 New
3,568 $45,000

Others Institutions Holding THRX

About Theseus Pharmaceuticals, Inc.


  • Ticker THRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,713,400
  • Description
  • Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...
More about THRX
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.